Summary of Significant Accounting Policies - License Agreements - LG Chem (Details) $ in Thousands		1 Months Ended	3 Months Ended
	Jan. 04, 2024 USD ($)	Jan. 31, 2024 USD ($) item person	Mar. 31, 2024 USD ($)
Significant Agreements
Issuance of common stock as consideration for LGC license			$ 18,716
L G Chem Ltd
Significant Agreements
Issuance of common stock as consideration for LGC license	$ 18,700
License agreement consideration payment	$ 40,000
Effective date of the license agreement	18 months
Aggregate payment upon achievement of development and commercial milestones	$ 205,000
License agreement | L G Chem Ltd
Significant Agreements
Number of patients | person		28
Number of doses participants | item		1
Period to check the primary end point of the treatment		98 days
Period of oral administration		364 days
Period of route trial		112 days
Number of enrolled patients | person		5
Cash payment		$ 40,000
Issuance of common stock as consideration for LGC license		18,700
License agreement consideration payment		$ 40,000
Effective date of the license agreement		18 months
Aggregate payment upon achievement of development and commercial milestones		$ 205,000
Maximum number of doses participants | item		3